Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.

Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, Guido R, Gesualdo L, Specchia G, Merlini G, Palladini G.

Blood Adv. 2020 Apr 14;4(7):1321-1324. doi: 10.1182/bloodadvances.2020001553. No abstract available.

PMID:
32251496
2.

Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis.

Caccialanza R, Cereda E, Klersy C, Milani P, Cappello S, Martinelli V, Turri A, Basset M, Borioli V, Nuvolone M, Caraccia M, Lavatelli F, Masi S, Lobascio F, Foli A, Merlini G, Palladini G.

Amyloid. 2020 Mar 26:1-6. doi: 10.1080/13506129.2020.1737004. [Epub ahead of print]

PMID:
32212933
3.

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.

Basset M, Defrancesco I, Milani P, Nuvolone M, Rattotti S, Foli A, Mangiacavalli S, Varettoni M, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G.

Blood. 2020 Jan 23;135(4):293-296. doi: 10.1182/blood.2019002762. No abstract available.

PMID:
31714952
4.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
5.

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis.

Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, Lavatelli F, Natalello A.

Anal Chem. 2019 Feb 19;91(4):2894-2900. doi: 10.1021/acs.analchem.8b05008. Epub 2019 Feb 4.

PMID:
30676723
6.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
7.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

PMID:
29101236
8.

The lung in amyloidosis.

Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170046. doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30. Review.

9.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G.

Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.

PMID:
28546143
10.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517. No abstract available.

PMID:
28434343
11.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.

Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):60-61. doi: 10.1080/13506129.2017.1292901. No abstract available.

PMID:
28434342
12.

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G.

Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644. No abstract available.

PMID:
28434326
13.

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):66-67. doi: 10.1080/13506129.2017.1293643. No abstract available.

PMID:
28434323
14.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
15.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G.

Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916. No abstract available.

PMID:
28434293
16.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
17.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024.

PMID:
28343171
18.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.

PMID:
28130212
19.

The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, Lavatelli F, Barassi A, Albertini R, Merlini G.

Clin Chem Lab Med. 2016 Jun 1;54(6):939-45. doi: 10.1515/cclm-2015-0985.

PMID:
26943606
20.

A patient with AL amyloidosis with negative free light chain results.

Milani P, Valentini V, Ferraro G, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Clin Chem Lab Med. 2016 Jun 1;54(6):1035-7. doi: 10.1515/cclm-2015-0847.

PMID:
26677890
21.

Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.

Caccialanza R, Palladini G, Cereda E, Bonardi C, Milani P, Cameletti B, Quarleri L, Cappello S, Foli A, Lavatelli F, Klersy C, Merlini G.

Nutrition. 2015 Oct;31(10):1228-34. doi: 10.1016/j.nut.2015.04.011. Epub 2015 May 11.

PMID:
26250487
22.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD.

Blood. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18.

PMID:
25987656
23.

A practical approach to the diagnosis of systemic amyloidoses.

Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G.

Blood. 2015 Apr 2;125(14):2239-44. doi: 10.1182/blood-2014-11-609883. Epub 2015 Jan 30.

PMID:
25636337
24.

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schönland S.

Blood. 2014 Oct 9;124(15):2325-32. doi: 10.1182/blood-2014-04-570010. Epub 2014 Aug 12.

PMID:
25115890
25.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G.

Leukemia. 2014 Dec;28(12):2311-6. doi: 10.1038/leu.2014.227. Epub 2014 Jul 25.

PMID:
25059496
26.

Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis.

Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, Foli A, Cappelli F, Perfetto F, Palladini G, Rapezzi C, Merlini G.

J Hypertens. 2014 May;32(5):1121-31; discussion 1131. doi: 10.1097/HJH.0000000000000120.

PMID:
24509117
27.

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, Caccialanza R, Perlini S, Merlini G.

Haematologica. 2014 Apr;99(4):743-50. doi: 10.3324/haematol.2013.095463. Epub 2013 Nov 8.

28.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G.

JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):891-4. doi: 10.1177/0148607113501328. Epub 2013 Sep 26.

PMID:
24072737
29.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G.

Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11.

PMID:
23479568
30.

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G.

Haematologica. 2013 Mar;98(3):433-6. doi: 10.3324/haematol.2012.073593. Epub 2012 Sep 14.

31.

Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.

Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G.

Am J Hematol. 2012 May;87(5):465-71. doi: 10.1002/ajh.23141. Epub 2012 Mar 3.

32.

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.

Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, Lavatelli F, Sarais G, Casarini S, Moratti R, Melzi d'Eril GV, Merlini G.

Amyloid. 2011 Dec;18(4):216-21. doi: 10.3109/13506129.2011.627069. Epub 2011 Nov 9.

PMID:
22070520
33.

A workflow management system for the biological samples exchange within the amyloidosis network.

Panzarasa S, Quaglini S, Ferrari R, Stefanelli M, Foli A, Palladini G, Russo P, Lavatelli F.

Amyloid. 2011 Jun;18 Suppl 1:233-5. doi: 10.3109/13506129.2011.574354088. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:235.

PMID:
21838500
34.

Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients.

Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G.

Amyloid. 2011 Jun;18 Suppl 1:92-3. doi: 10.3109/13506129.2011.574354033. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:93.

PMID:
21838445
35.

The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients.

Foli A, Palladini G, Caporali R, Verga L, Morbini P, Obici L, Russo P, Sarais G, Donadei S, Montecucco C, Merlini G.

Amyloid. 2011 Jun;18 Suppl 1:80-2. doi: 10.3109/13506129.2011.574354029. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:82.

PMID:
21838441
36.

Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits.

Lavatelli F, Valentini V, Palladini G, Verga L, Russo P, Foli A, Obici L, Sarais G, Perfetti V, Casarini S, Merlini G.

Amyloid. 2011 Jun;18 Suppl 1:64-6. doi: 10.3109/13506129.2011.574354023. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:66.

PMID:
21838435
37.

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G.

Ann Hematol. 2012 Mar;91(3):399-406. doi: 10.1007/s00277-011-1309-x. Epub 2011 Aug 9.

PMID:
21826471
38.

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.

Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G.

Ann Hematol. 2012 Jan;91(1):89-92. doi: 10.1007/s00277-011-1244-x. Epub 2011 Apr 30.

PMID:
21533608
39.

Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.

Palladini G, Foli A, Russo P, Milani P, Obici L, Lavatelli F, Merlini G.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):143-5. doi: 10.3816/CLML.2011.n.033.

PMID:
21454217
40.

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d'Eril GV, Merlini G.

Blood. 2010 Nov 4;116(18):3426-30. doi: 10.1182/blood-2010-05-286567. Epub 2010 Jul 19.

41.

HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell response.

Paolucci S, Foli A, Gulminetti R, Calarota SA, Maserati R, Baldanti F, Gerna G.

Curr HIV Res. 2009 May;7(3):302-10.

PMID:
19442126
42.

AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.

Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, Bragotti LZ, Perfetti V, Obici L, Bergesio F, Albertini R, Moratti R, Merlini G.

Clin Lymphoma Myeloma. 2009 Mar;9(1):80-3. doi: 10.3816/CLM.2009.n.021.

PMID:
19362981
43.

Beneficial effect of TRAIL on HIV burden, without detectable immune consequences.

Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD.

PLoS One. 2008 Aug 28;3(8):e3096. doi: 10.1371/journal.pone.0003096.

44.

HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F.

J Immunol. 2008 May 1;180(9):5907-15.

45.

A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication.

Foli A, Maiocchi MA, Lisziewicz J, Lori F.

J Infect Dis. 2007 Nov 1;196(9):1409-15. Epub 2007 Sep 26.

PMID:
17922407
46.

Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.

Maserati R, Foli A, Tomasoni L, Sighinolfi L, Maggiolo F, Sacchini D, Di Pietro M, Bertelli D, Tinelli C, Lori F.

Curr HIV Res. 2007 May;5(3):337-43.

PMID:
17504175
47.

Virostatics: a new class of anti-HIV drugs.

Lori F, Foli A, Kelly LM, Lisziewicz J.

Curr Med Chem. 2007;14(2):233-41. Review.

PMID:
17266582
48.

Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options.

Lori F, Foli A, Lisziewicz J.

Curr Opin HIV AIDS. 2007 Jan;2(1):14-20. doi: 10.1097/COH.0b013e328011aad6.

PMID:
19372860
49.

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.

Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J.

AIDS. 2005 Jul 22;19(11):1173-81.

PMID:
15990570
50.

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72.

PMID:
15943568

Supplemental Content

Support Center